Core Viewpoint - The article highlights the successful IPO of Silver Pharma (02591.HK) on the Hong Kong Stock Exchange, marking it as the latest addition to the biotech sector, with significant oversubscription and a focus on its core product, Isu-Paglutide A [2][3]. Group 1: IPO Details - Silver Pharma's IPO was priced at HKD 18.68 per share, resulting in a market capitalization exceeding HKD 8.5 billion [2]. - The company raised HKD 683 million, with a net amount of HKD 610 million after expenses, allocating approximately 90% of the funds towards clinical trials and commercialization of Isu-Paglutide A [2][3]. Group 2: Product Focus - Isu-Paglutide A is a human-derived long-acting GLP-1 receptor agonist approved in China for treating Type 2 Diabetes (T2D) [5]. - Phase III clinical data indicates an average reduction in HbA1c of 1.1% after 4 weeks and 2.2% after 24 weeks at a 3.0 mg dosage, with a 60% diabetes remission rate observed in newly diagnosed T2D patients after a three-month cessation of treatment [5]. Group 3: Future Plans - The company plans to officially commercialize Isu-Paglutide A in China by February 2025 and is currently advancing its production capabilities through partnerships with CDMOs, with future plans to establish its own production facilities [7].
速递｜认购5364倍，首日暴涨近300%！银诺医药今天在港上市